相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases
Elena Miranda et al.
CANCER (2013)
c-Kit Is Suppressed in Human Colon Cancer Tissue and Contributes to L1-Mediated Metastasis
Nancy Gavert et al.
CANCER RESEARCH (2013)
Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial
Josep Tabernero et al.
CLINICAL CANCER RESEARCH (2013)
Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial
Alfredo Carrato et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
Carsten Bokemeyer et al.
EUROPEAN JOURNAL OF CANCER (2012)
Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
Sabine Tejpar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
STEM CELL FACTOR RECEPTOR/c-KIT: FROM BASIC SCIENCE TO CLINICAL IMPLICATIONS
Johan Lennartsson et al.
PHYSIOLOGICAL REVIEWS (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Impact of BRAF Mutation and Microsatellite Instability on the Pattern of Metastatic Spread and Prognosis in Metastatic Colorectal Cancer
Ben Tran et al.
CANCER (2011)
Loss of E-cadherin independently predicts the lymph node status in colorectal cancer
E. Karamitopoulou et al.
PATHOLOGY (2011)
Clinical Significance of Microvessel Count in Patients with Metastatic Liver Cancer Originating from Colorectal Carcinoma
Atsushi Nanashima et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer
Otto Schmalhofer et al.
CANCER AND METASTASIS REVIEWS (2009)
TGF-alpha Expression as a Potential Biomarker of Risk Within the Normal-appearing Colorectal Mucosa of Patients with and without Incident Sporadic Adenoma
Carrie R. Daniel et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer
Y. J. Fang et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2009)
Prognostic Significance and Molecular Associations of 18q Loss of Heterozygosity: A Cohort Study of Microsatellite Stable Colorectal Cancers
Shuji Ogino et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
BRAF Mutation in Metastatic Colorectal Cancer.
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Genetic prognostic and predictive markers in colorectal cancer
Axel Walther et al.
NATURE REVIEWS CANCER (2009)
Expression of SDF-1α and nuclear CXCR4 predicts lymph node metastasis in colorectal cancer
N. Yoshitake et al.
BRITISH JOURNAL OF CANCER (2008)
Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis
A. Walther et al.
GUT (2008)
hTERT expression in colorectal adenocarcinoma: correlations with p21, p53 expressions and clinicopathological features
Alfred King-Yin Lam et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients
Joan Maurel et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer
Yoon-Jung Boo et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
TGF-β signaling alterations and susceptibility to colorectal cancer
Yanfei Xu et al.
HUMAN MOLECULAR GENETICS (2007)
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
Gershon Y. Locker et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer
Neal J. Meropol et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Molecular prognostic markers in resectable colorectal liver metastases: A systematic review
C. P. Neal et al.
EUROPEAN JOURNAL OF CANCER (2006)
Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome
Joseph Kim et al.
ANNALS OF SURGERY (2006)
Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature
G. Des Guetz et al.
BRITISH JOURNAL OF CANCER (2006)
CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment
JA Burger et al.
BLOOD (2006)
Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline
CE Desch et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
P53 mutation analysis of colorectal liver metastases: Relation to actual survival, angiogenic status, and p53 overexpression
KP de Jong et al.
CLINICAL CANCER RESEARCH (2005)
Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer
M Langenskiöld et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2005)
Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival
J Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
L1, a novel target of β-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers
N Gavert et al.
JOURNAL OF CELL BIOLOGY (2005)
Thymidylate synthase expression and prognosis in colorectal cancer: A systematic review and meta-analysis
S Popat et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Soluble serum E-cadherin as a marker of tumour progression in colorectal cancer patients
C Wilmanns et al.
CLINICAL & EXPERIMENTAL METASTASIS (2004)
Expression of the proto-oncogene c-KIT in normal and tumor tissues from colorectal carcinoma patients
I Sammarco et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2004)
Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients
MG Tutton et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer
W Ichikawa et al.
BRITISH JOURNAL OF CANCER (2003)
Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer
M Gonen et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis
ET Waas et al.
BRITISH JOURNAL OF SURGERY (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy:: Phenotypic and genotypic analyses
MC Etienne et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Relevance of biologic markers in colorectal carcinoma - A comparative study of a broad panel
C Barozzi et al.
CANCER (2002)
New functions for the matrix metalloproteinases in cancer progression
M Egeblad et al.
NATURE REVIEWS CANCER (2002)
APC, signal transduction and genetic instability in colorectal cancer
R Fodde et al.
NATURE REVIEWS CANCER (2001)
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
HJN Andreyev et al.
BRITISH JOURNAL OF CANCER (2001)
Clinical significance of E-cadherin-catenin complex expression in metastatic foci of colorectal carcinoma
M Ikeguchi et al.
JOURNAL OF SURGICAL ONCOLOGY (2001)
Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
T Watanabe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Vascular endothelial growth factor (VEGF) -: a valuable serum tumour marker in patients with colorectal cancer?
R Broll et al.
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY (2001)
Mechanisms of disease:: Role of transforming growth factor β in human disease.
GC Blobe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients
JC Lee et al.
EUROPEAN JOURNAL OF CANCER (2000)
Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer
R Gryfe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
